about
Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF).Data on the quantitative assessment pulmonary ground-glass opacification from coronary computed tomography angiography datasets.Risk stratification in emergency patients by copeptinExtracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).NT-ProBNP independently predicts long-term mortality in patients admitted for coronary angiography.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with theHigh sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy.Carnitine levels in skeletal muscle, blood, and urine in patients with primary carnitine deficiency during intermission of L-carnitine supplementationStrong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice.Survival differences between heart failure in general practices and in hospitals.Clinical and prognostic correlates of pulmonary congestion in coronary computed tomography angiography data sets.Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study.Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency.Evaluation of Commercial Self-Monitoring Devices for Clinical Purposes: Results from the Future Patient Trial, Phase I.High-sensitivity C-reactive protein and exercise-induced changes in subjects suspected of coronary artery disease.Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS).Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study.Coronary flow reserve as a link between diastolic and systolic function and exercise capacity in heart failure.Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke.Mild Hypokalemia and Supraventricular Ectopy Increases the Risk of Stroke in Community-Dwelling Subjects.Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation.Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study.Long-term prognostic significance of homocysteine in middle-aged and elderly.The circadian variation of premature atrial contractions.Ambulatory cardiac arrhythmias in relation to mild hypokalaemia and prognosis in community dwelling middle-aged and elderly subjects.Diagnosing left ventricular hypertrophy in arterial hypertension.Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.Value of left ventricular filling parameters to predict mortality and functional class in patients with heart disease from the community.Accuracy of a heart failure diagnosis in administrative registers.Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands.Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study.Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease.Troponin T is a strong marker of mortality in hospitalized patients.Primary Carnitine deficiency in the Faroe Islands: health and cardiac status in 76 adult patients diagnosed by screening.Mild hyponatremia carries a poor prognosis in community subjects.Increased hsCRP is associated with higher risk of aortic valve replacement in patients with aortic stenosis.EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot).EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).
P50
Q30908639-8FD984FA-D630-4EDB-9249-EBFC9536CA6DQ31148182-3960EAE4-A4C8-45B5-96DF-279F27D6060DQ33740059-12DB080F-95D0-4B28-9E7D-16716A78BB67Q33889897-4E0F2042-9258-4A88-9C0E-91B6470B8F82Q34306307-448A355B-9035-4696-BFA5-E407957A9236Q34640762-934C87EE-F83D-4DDE-A1F5-DFA79A5991CBQ35065597-362F3398-DF1C-457F-9E44-048831093357Q35220712-5295835C-FF2F-4573-B08C-D809AC2C57A9Q35380284-BC363EA1-1D9F-42DA-AEEA-C1BE90EFC3CDQ35574257-F16B2527-ACEA-4E58-98A8-336B2D38ECDFQ36158166-6A38F4A6-D603-42CC-8760-22B8457936C8Q37125983-C7323D68-7AEB-4030-9939-28325181FFB7Q37352819-039A7D3A-EE1C-4C11-AD72-5C21E3CC0022Q37434019-694C673A-35A1-40FC-9346-E95E68AB99A7Q37632743-F321FCFF-8AC3-4715-82BB-A678A2B66424Q37688165-C8491E00-BAAA-4395-ACBF-48466922424BQ38389279-DF1BA531-8518-4852-89F2-82BCC7DF7EF0Q38420241-0197DBB8-B970-4E5F-B990-69299A4DEAF9Q39516585-9016A541-030F-46FA-A57C-25CDF80184E8Q39754261-17D9C45A-CF0B-485F-A9B0-285A7477F8F0Q39929393-0437CC59-3E89-4A92-A43E-6344F20D7071Q40345599-D2DFFBA0-E7B9-496C-854B-0E626635F9FEQ40726281-2BD8CB51-C883-49DF-83CB-4E8ED1159718Q40747277-1BC8D8BB-3647-4EA3-9286-C8165095E9C1Q40836256-62880B2D-85E7-4C5A-B6DB-D4FD881E6DDFQ41020450-00C43543-A0AF-4497-B82F-C494B8159B18Q41465336-8C7D1F21-3917-43CE-9BAF-07BFDC8A8914Q42539395-82EABD82-D630-4DE7-AE70-EA54F06F4059Q43424804-B509B92B-E1D9-498E-AAD5-3FF2BB84502FQ43631693-8761BCE4-22E1-44AC-94FA-D5E35D36390BQ43737933-B996233D-18FB-4A7C-B4C5-9AE46713A5E2Q43776338-E3142822-B0DE-4B6D-9D4E-E85D0353969BQ44100952-DD98A91B-E77C-493A-81C7-4C863E1920B8Q44806693-90E238FB-4CC3-4FD5-B917-B75A7FE5E238Q44920907-0E7C481E-EE0A-40F4-BFF2-EF47FA603FEEQ44929080-6FA8C245-28A1-45BC-9282-89DEBB7FC2A5Q45950574-2A84F63A-D135-498B-BC6C-9DA519C69DB5Q46162925-4C4AC16B-3280-45E4-92BD-4B59F3C938CBQ46275793-80B152F1-8944-45E9-AFFE-6AF300ECFAFDQ46414626-397C2291-A9B8-45F7-AE4B-15D432D23C66
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Olav Wendelboe Nielsen
@ast
Olav Wendelboe Nielsen
@en
Olav Wendelboe Nielsen
@es
Olav Wendelboe Nielsen
@nl
Olav Wendelboe Nielsen
@sl
type
label
Olav Wendelboe Nielsen
@ast
Olav Wendelboe Nielsen
@en
Olav Wendelboe Nielsen
@es
Olav Wendelboe Nielsen
@nl
Olav Wendelboe Nielsen
@sl
prefLabel
Olav Wendelboe Nielsen
@ast
Olav Wendelboe Nielsen
@en
Olav Wendelboe Nielsen
@es
Olav Wendelboe Nielsen
@nl
Olav Wendelboe Nielsen
@sl
P106
P21
P31
P496
0000-0003-3532-9431